Literature DB >> 6141053

Concentration-effect and time-effect relationships of carteolol.

T Ishizaki, A Ohnishi, T Sasaki, K Chiba, T Suganuma, K Kushida.   

Abstract

The concentration-beta blocking effect and time-effect relationships of carteolol were examined in eight normal adults given 15 mg i.v. and 20 mg orally on separate occasions. Resting and post-exercise blood pressures and heart rates were assessed before and at various times up to 48 h after each dose. Carteolol, a beta-blocker with some partial agonist activity, produced an insignificant, transient increase in heart rate 2 to 6 h after both doses, and a fall (p less than 0.05) in diastolic blood pressure 4 and 6 h after the intravenous dose and 6 h after the oral dose in the resting supine position, as compared to the corresponding baseline values. All values of the post-exercise heart rate and the double product after each of the doses were significantly (p less than 0.001) below the baseline values for the entire period (48 h) of observation. A significant correlation between the log plasma carteolol concentration (log C) and its beta-blocking effect (E: p less than 0.001, r = 0.508 i.v.; p less than 0.001, r = 0.626, p.o.) was found. The r-values for individuals were higher (0.852 to 0.977, intravenous; 0.817 to 0.981, oral) than for the group as a whole. The slope (m) of the relationship, E = m X log C + r, showed a certain variance within and between individuals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141053     DOI: 10.1007/bf00542514

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  40 in total

Review 1.  The clinical pharmacology of beta-adrenoceptor-blocking drugs.

Authors:  M E Conolly; F Kersting; C T Dollery
Journal:  Prog Cardiovasc Dis       Date:  1976 Nov-Dec       Impact factor: 8.194

2.  Intrinsic heart rate on exercise and the measurement of beta-adrenoceptor blockade.

Authors:  S G Carruthers; R G Shanks; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

3.  Propranolol and cardiac surgery.

Authors:  J F Viljoen; F G Estafanous; G A Kellner
Journal:  J Thorac Cardiovasc Surg       Date:  1972-11       Impact factor: 5.209

Review 4.  The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs.

Authors:  B N Prichard; R J Walden
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

5.  Plasma levels and effects of metoprolol after single and multiple oral doses.

Authors:  P Collste; K Haglund; C von Bahr
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

6.  Activity and duration of action of pindolol and alprenolol compared in healthy volunteers.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

7.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

8.  Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia.

Authors:  G L Jennings; A Bobik; E T Fagan; P I Korner
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

9.  Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent beta-adrenergic blocking agent.

Authors:  Y Yabuochi; D Kinoshita
Journal:  Jpn J Pharmacol       Date:  1974-12

10.  Duration of action of beta blockers.

Authors:  S R Johansson; M McCall; C Wilhelmsson; J A Vedin
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

View more
  6 in total

1.  Metabolic effects of carteolol and dilevalol in essential hypertension.

Authors:  T Baba; K Takebe; T Tomiyama
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.

Authors:  R Koopmans; B Oosterhuis; J M Karemaker; J Wemer; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma.

Authors:  A Wellstein; D Palm; G Wiemer; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Kushida; Y Horai; K Chiba; T Suganuma
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

6.  Effect of beta-adrenoceptor blockade on exercise-induced plasma catecholamine concentrations and their dissipation profile.

Authors:  A Ohnishi; A Minegishi; T Sasaki; T Suganuma; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.